Introduction
Within all gynecological malignancies, ovarian cancer is the leading cause of death in Chinese women (Cao, 2004) . In the initial, symptom-free stage of the disease, approximately two-thirds of patients will have developed peritoneal and lymph node metastasis. The overall 5-year survival rate of advanced ovarian cancer is roughly 20-25%. Therefore, cytoreductive surgery alone is an insufficient treatment, and the prognosis for the patient mainly depends on cancer responsiveness to subsequent chemotherapy.
The standard first-line chemotherapy for advanced ovarian cancer is a combination of platinum with either cyclophosphamide or paclitaxel administered after surgery (du et al., 2004) . However, 30% of patients do not respond to platinum-based chemotherapy in the first attempt. Platinum agents are known to act through the formation of interstrand and intrastrand DNA cross-links, thereby changing the DNA conformation, which may affect the replication of DNA and inhibit its synthesis (Zambl et al., , Pei Hu 1 , Yan Li 2 * 1995). One of the mechanisms by which the tumor cells develop resistance to platinum agents is by the enhanced repair of bulky DNA adducts (Reed, 1998) . Therefore, DNA repair capacity (DRC) is an important determinant of the resistance to platinum agents. The four main DNA repair pathways are: base excision repair (BER), nucleotide excision repair (NER), double strand break repair (DSBR) and mismatch repair (MMR). The BER and NER pathways contribute to repairing a broad spectrum of chemical adducts, DNA damage induced by UV and ionizing radiation as well as intraand interstrand crosslinks. In NER pathway, the XPC participates in DNA damage-induced DNA distortion recognition and DNA repair initiation by binding to the HR23B to form the XPC-HR23B complex (Masutani et al., 1994) , while the DNA helicase XPD takes part in the unwinding of DNA and formation of a complex with TFIIH for DNA repair. The XRCC1 genes in the BER pathway act as a scaffold in the removal of adducts through both single-strand break repair and base excision repair, and in the repair of other types of cisplatin-induced damage, such as double-strand breaks, through a nonhomologous end-joining pathway (Lindahl et al., 1999; Weaver et al., 2005) . In vitro and in vivo studies have demonstrated that those genes in the NER and BER pathway are involved in the pharmacokinetics of platinum-based drugs and platinum resistance of cancer patients (Rosell et al., 2003; Azuma et al., 2007; Walsh et al., 2008) .
Single nucleotide polymorphisms (SNPs) in any of the NER and BER genes may modulate DRC and contribute to individual variations in chemotherapy response (Yu et al., 2008; Kalikali et al., 2009; Sun et al., 2009; Fleming et al., 2012) . Based on previous reports, we chose 8 single nucleotide polymorphisms (SNPs) of the XPC, XPD, XRCC1 genes (Saldivar et al., 2007; Qiu et al., 2008; Sun et al., 2009; Ji et al., 2012) and investigated the association between these SNPs and the response to platinum-based chemotherapy in patients with epithelial ovarian cancer.
Materials and Methods

Study population
The study included 213 patients who had presented for treatment of ovarian cancer to the Fourth Affiliated Hospital, Hebei Medical University, between 2002 and 2008. Eligibility criteria for this cohort included newly diagnosed, histologically confirmed primary epithelial ovarian cancer in women of any age and Han nationality. Patients were excluded from this study if they had neoadjuvant chemotherapy, any chemotherapy before surgical staging, concurrent primary neoplasms, or benign ovarian disease. The mean age of patients was 54 years (range 22-75 years). All patients had been evaluated according to the FIGO surgical staging system. Patients with early-stage cancer (FIGO stage IB-IIC) received 3 to 5 cycles of platinum-based combination chemotherapy after cytoreductive surgery; the other patients with advanced-stage cancer (FIGO stage IIIA-IV) received 6 to 9 cycles. Optimal debulking surgery was defined a maximal residual tumor diameter of 1 cm or less, whereas a maximal residual tumor diameter more than 1 cm meant suboptimal debulking surgery. The first-line chemotherapy protocol included platinum compounds 1 to 2 weeks after surgery, cisplatin (75 mg/m 2 ) or carboplatin (AUC 5, Calvert's formula) and cyclophosphamide (700 mg/m 2 ) or paclitaxel (175 mg/m 2 ) were administered intravenously (IV) every 3-4 weeks for 6 cycles. Both overall survival (OS) and progression-free survival (PFS) were used to evaluate the survival status of patients. The study was approved by the Ethics Committee of Hebei Cancer Institute, and informed consent was obtained from all recruited subjects.
DNA extraction
Venous blood (5 ml) from each subject was drawn into Vacutainer tubes containing EDTA and stored at 4°C. After collection, genomic DNA was extracted within one week by proteinase K (Merck, Darmstadt, Germany) digestion followed by a desalting procedure, according to the method published by Miller et al. (1988) .
Determination of the Genotypes
The 8 SNPs, which included Arg194Trp, Arg280His and Arg399Gln in the XRCC1 gene, Ala499Val, Lys939Gln and PAT+/-in the XPC gene, and Asp312Asn and Lys751Gln in the XPD gene, were genotyped using the restriction fragment length polymorphism (RFLP) and the primer introduced restriction analysis (PIRA) method. Additional details, including the location of SNPs in the respective genes, the PCR conditions and restriction enzyme with product sizes are presented in Table 1 . Briefly, the DNA sequence containing the relevant polymorphic site was amplified by polymerase chain reaction (PCR), and the product was digested with an appropriate restriction enzyme that cleaves only 1 of the 2 alleles. The digests were then subjected to gel electrophoresis and visualized by ethidium bromide staining. The genotype of the XPC PAT+/-[PAT: poly (AT)] polymorphism was determined by primerintroduced restriction analysis-polymerase chain reaction (PIRA-PCR). For a negative control, distilled water, instead of DNA in the reaction system, was used in each PCR plate. For 10% of the samples, the PCR reactions were repeated for quality control.
Statistical analysis
Statistical analysis was performed using the SPSS 13.0 software package (SPSS Company, Chicago, IL, USA). Survival analyses were performed using the Kaplan-Meier analysis with log-rank and Breslow test. The association of each SNP with the risk of recurrence and death was analyzed by the Cox proportional hazard model, adjusting for age, stage, grade, tumor residual, and histology. A probability level of 5% was considered significant.
Results
Patients' characteristics
Among all patients, 140 (65.7%) responded to the first-line therapy (median time of recurrence was 35.5 month), whereas 73 (34.3%) did not respond to the therapy (median time of recurrence was 4 months). The distribution of 8 SNP genotype frequencies did not significantly deviate from that expected for a HardyWeinberg equilibrium (all P values > 0.05). The clinical characteristics of patients with epithelial ovarian cancer and their relationship to treatment outcome are listed in Table 2 . Table 3 illustrates the link between the clinical characteristics of patients and the frequencies of 8 SNP genotypes. For the XPC Ala499Val polymorphism, the frequency of the Ala/Ala genotype is significantly higher in stage III-IV patients than in stage I-II patients (P=0.03). For the XPD Asp312Asn polymorphism, there is a borderline significance between the distribution of genotype frequency and the histological type of patients (P=0.05).
Association between polymorphisms and the clinical outcome of patients treated with platinum-based chemotherapy
XPC: The median PFS of patients carrying the Lys/ Lys and Lys/Gln+Gln/Gln genotype of the XPC Lys/Gln polymorphism was 25 and 12 months, respectively; and the mean OS of those patients was 31.1 and 27.8 months, respectively. Survival analysis showed that the XPC Lys/Gln polymorphism was associated with prognosis of epithelial ovarian cancer patients (Figure 1A and 1B; Table 4 ). Compared with the Lys/Lys genotype, patients carrying the Lys/Gln+Gln/Gln genotype had a shorter median PFS and median OS time. Kaplan-Meier plots illustrate the differences in PFS ( Figure 1A ; P=0.039) and OS ( Figure 1B ; P=0.048) distributions for patients categorized by XPC Lys/Gln polymorphisms. However, after adjusting for the prognostic factors (age, FIGO stage, grade, tumor residual size and histology), patients with the Lys/Gln+Gln/Gln genotype only had an increased risk of death (HR=1.75; 95% CI=1.06-2.91) compared with those carrying the Lys/Lys genotype (Table 4) . XRCC1 and XPD: There were no significant relationships between the genotype distributions of five SNPs (XRCC1 Arg194Trp, Arg280His, Arg399Gln and XPD Asp312Asn, Lys751Gln) and the clinical outcome of ovarian cancer patients treated with platinum-based chemotherapy. Compared with the genotypes of wild-type homozygous, the variant homozygous and heterozygous genotypes were not associated with disease progression or death (Table 4) .
Discussion
Clinical cancer outcomes and responsiveness to platinum-based chemotherapy are attributable to some SNPs of the NER and BER pathway genes (Yu et al., 2008; Kalikali et al., 2009; Sun et al., 2009 ). However, reports on these polymorphisms and their effects on epithelial ovarian cancer are limited in the literature. :http://dx.doi.org/10.7314/APJCP.2013.14.2 
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Previous studies showed that polymorphisms of Arg194Trp and Arg399Gln in the XRCC1 gene, PAT+/-in the XPC gene, and Asp312Asn and Lys751Gln in the XPD gene were not associated with the response rate of epithelial ovarian cancer to platinum-based chemotherapy (Saldivar et al., 2007; Kim et al., 2009) . Our data also showed no significant link between genotype frequencies of these five polymorphisms and the clinical outcome of Chinese ovarian cancer patients treated with platinumbased chemotherapy. However, our study suggested that the XPC Lys/Gln polymorphism may be associated with the PFS and OS of ovarian cancer patients treated with platinum-based chemotherapy, i.e., patients carrying the Gln allele may have a shorter OS than those with the Lys/ Lys genotype. To the best of our knowledge, this is the first study to assess genetic polymorphisms of Arg280His in the XRCC1 gene and Ala499Val and Lys939Gln in the XPC gene as predictive biomarkers of platinum-based chemotherapy response in EOC.
The XPC gene encodes a 125 kDa protein, which binds to HR23B to form the XPC-HR23B complex. The complex is involved in DNA damage recognition and DNA repair initiation in the NER pathway, a key pathway, which helps mediate resistance or sensitivity to platinum chemotherapeutic agents (Masutani et al., 1994) . Polymorphisms in the coding and regulatory regions of the XPC gene may alter gene expression and thereby modulate the DNA repair function. The three most common polymorphisms are Ala499Val (CgT), PAT (-/+), and Lys939Gln (AgC), which have been associated with increased risks for many human malignancies. A recent meta-analysis study (Qiu et al., 2008) showed that, compared to their corresponding wild-type homozygous genotypes, the variant 939Gln homozygous genotype was a risk factor for developing lung cancer (OR=1.28, 95% CI=1.07-1.53), whereas the 499Val variant homozygous genotype was a risk factor for developing bladder cancer (OR=1.33, 95% CI=1.06-1.68). However, there were few studies about the association between three SNPs and platinum-based chemotherapy for cancer. Saldivar et al. (2007) reported that the polymorphism of XPC PAT (-/+) was not associated with responsiveness to platinum-based chemotherapy for ovarian cancer. However, a higher response rate was found in patients with advanced nonsmall cell lung cancer with the XPC PAT +/+ genotype compared to those that had the XPC PAT -/-genotype (Yuan et al., 2005) . In this paper, Kaplan-Meier analysis showed that EOC patients carrying the 939Gln allele of the XPC Lys939Gln polymorphism may increase the risk of disease recurrence and death. Further, the Cox regression model adjusting clinical characteristics (include age, stage, grade, residual tumor size, and histology) analysis suggested that the survival rate in ovarian cancer patients with the 939Gln allele is lower than in those with the Lys/Lys genotype. However, no association was found between Ala499Val, PAT (-/+) polymorphisms and clinical outcomes in epithelial ovarian cancer treated with platinum-base chemotherapy. The Ala499Val, PAT (-/+), and Lys939Gln polymorphisms are located at exon 8, intron 9, and exon 15 of the XPC gene, respectively. The functions of these three polymorphisms are unclear, although some studies on the link between XPC protein expression and Lys939Gln polymorphism have been reported (Khan et al., 2000; Khan et al., 2002) . Thus, our study was unable to unravel the mechanism of action by which Lys939Gln influences the response rate of EOC to platinum-based chemotherapy. Because our study samples were limited, more studies are needed to examine a greater sample size and breadth of cancers.
The XPD (also known as ERCC2) gene encodes for a DNA helicase, which is involved in the unwinding of DNA and forms a complex with transcription factor IIH during DNA repair. Mutations in XPD cause a severe but variable suppression of NER. Two nonsynonymous SNPs were described in the XPD gene and were located at codons 312 (exon 10 GgA, AspgAsn) and 751 (exon 23 AgC, LysgGln). It is not known whether these polymorphisms have functional effects. However, it is suggested that the Lys/Lys genotype of the XPD Lys/Gln polymorphism is susceptible to X-ray-induced chromatid aberrations, while no effect has been noted on lymphocyte sister chromatid exchanges. The associations between XPD Asp312Asn and Lys751Gln SNPs and platinum-based chemotherapy have been reported in some cancers, including lung cancer (Giachino et al., 2007) and colorectal carcinoma (Park et al., 2001 ), but the results were inconsistent. Saldivar et al., (2007) showed that the carriers of at least one variant allele of the exon10 (Asp312Asn) SNP had a significantly reduced risk of death in epithelial ovarian cancer patients; the association was similar for exon23 (Lys751Gln) SNP. However, no association was found between these variant alleles and responsiveness to platinum-based chemotherapy. The results of our analysis on the XPD polymorphisms show that there are no associations between carriers of different genotypes and the clinical outcome of epithelial ovarian cancer treated with platinum-based chemotherapy in Chinese women.
The XRCC1 is an important gene in the base excision repair pathway. However, the study showed that the XRCC1 protein physically interacts with ligase III and poly (ADP-ribose) polymerase, which is thought to act as a scaffold in the removal of adducts through both singlestrand break repair and base excision repair (Lindahl et al., 1999) . The XRCC1 protein also acts in the repair of other types of cisplatin-induced damage, including doublestrand breaks, through a nonhomologous end-joining pathway, which is an alternative to the predominant ATM-XRCC4-DNA ligase IV pathway (Weaver et al., 2005) . More than 60 SNPs were identified within the human population. Considering the amino acid substitutions and relatively high frequency, the Arg194Trp (R194W), Arg280His (R280H) and Arg399Gln (R399Q) SNPs have been studied more extensively. XRCC1 Arg194Trp and Arg399Gln may be associated with clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer, but the results are inconsistent (Kalikali et al., 2009; Sun et al., 2009) . Kim et al. (2009) showed that among the Korean population, XRCC1 Arg194Trp and Arg399Gln polymorphisms may not affect drug response, toxicity and survival in patients with EOC who received taxane-and platinum-based chemotherapy after surgery (Yu et al., 2008) . Our study results also suggested that among the Chinese population, the XRCC1 Arg194Trp, Arg280His and Arg399Gln polymorphisms were not associated with survival rates in EOC patients treated with platinum-based chemotherapy.
Our study included a very heterogeneous population of patients. For example, in our sample, patients had early stage (31.9%) and late stage (68.1%) cancers of various grades and histologies. However, the study's results were still useful in evaluating the clinical outcomes of patients who were treated with platinum-based chemotherapy. Firstly, statistical analysis demonstrated a significant relationship between the genotype distributions and the FIGO stage of patients with the XPC (Ala499Val) polymorphism. Secondly, the association between the Gln allele of the XPC Lys939Gln polymorphism and the risk of disease recurrence and death was confirmed using both univariate and multivariate analysis.
In conclusion, our study indicated that the XPC Lys939Gln polymorphisms may correlate to the clinical outcome of EOC patients treated with platinum-based chemotherapy. If confirmed in larger samples and further perspective studies, the XPC SNP might serve as biomarkers for EOC patient's personalized chemotherapy of platinum-based anticancer drugs. Therefore, evaluation of the genetic polymorphisms, especially those on DNA repair gene, in clinical outcome of cancer patients may help us to identify the individuals at higher risk of developing resistance to platinum-based chemotherapy.
